These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28495318)

  • 1. The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?
    Palau V; Riera M; Soler MJ
    Endocrinol Diabetes Nutr; 2017 May; 64(5):237-240. PubMed ID: 28495318
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
    Bell RM; Yellon DM
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):435-437. PubMed ID: 29030201
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 4. Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus.
    Patoulias D; Eid AH; Rizzo M
    J Diabetes Complications; 2023 Dec; 37(12):108630. PubMed ID: 39034649
    [No Abstract]   [Full Text] [Related]  

  • 5. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction.
    Chilton RJ
    Am J Cardiol; 2017 Jul; 120(1S):S1-S3. PubMed ID: 28606339
    [No Abstract]   [Full Text] [Related]  

  • 8. Results from Cardiovascular Outcome Trials in Diabetes.
    Muñoz Torres M; Muñoz Garach A
    Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
    [No Abstract]   [Full Text] [Related]  

  • 9. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
    Vettor R; Inzucchi SE; Fioretto P
    Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
    [No Abstract]   [Full Text] [Related]  

  • 10. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
    MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
    [No Abstract]   [Full Text] [Related]  

  • 11. [Diabetes mellitus. SGLT2 inhibitor reduces cardiovascular mortality].
    Overbeck P
    MMW Fortschr Med; 2015 Oct; 157(17):16. PubMed ID: 26759859
    [No Abstract]   [Full Text] [Related]  

  • 12. Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
    Slomski A
    JAMA; 2022 Sep; 328(9):817. PubMed ID: 36066528
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of empagliflozin on diabetic kidney disease.
    Koya D
    J Diabetes Investig; 2017 Sep; 8(5):658-660. PubMed ID: 28035769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
    [No Abstract]   [Full Text] [Related]  

  • 16. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
    Jørgensen NB; Pedersen J; Vaag AA
    J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cardiovascular protection of diabetic patient with chronic renal disease and particular case of end-stage renal disease in elderly patients].
    Zaoui P; Hannedouche T; Combe C
    Nephrol Ther; 2017 Jun; 13(6S):6S16-6S24. PubMed ID: 29463395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihyperglycemic medications for cardiovascular disease risk reduction.
    Goldman JD
    Am J Manag Care; 2018 Aug; 24(13 Suppl):S273-S278. PubMed ID: 30160394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
    Staels B
    Am J Cardiol; 2017 Jul; 120(1S):S28-S36. PubMed ID: 28606341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.